Breaking News

Nomura, MUFJ-MS, Goldman, JPMorgan to Lead Japan Post IPO
Tweet TWEET

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2012 Financial Results and Corporate Update on March 7, 2013

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2012 Financial 
Results and Corporate Update on March 7, 2013 
CAMBRIDGE, MA -- (Marketwire) -- 02/20/13 --  Sarepta Therapeutics,
Inc. (NASDAQ: SRPT), a developer of innovative RNA-based
therapeutics, will report fourth quarter and full-year 2012 financial
results before the NASDAQ Global Market opens on Thursday, March 7,
2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific
Time), Chris Garabedian, Sarepta's President and CEO, will host a
conference call to discuss fourth quarter and full-year financial
results and to provide a corporate update.  
The conference call may be accessed by dialing 800.446.2782 for
domestic callers and 847.413.3235 for international callers. The
passcode for the call is 34143150. Please specify to the operator
that you would like to join the "Sarepta Fourth Quarter and Full-Year
2012 Earnings Call." The conference call will be webcast live under
the events section of Sarepta's website at
www.sareptatherapeutics.com and will be archived there following the
call for 90 days. Please connect to Sarepta's website several minutes
prior to the start of the broadcast to ensure adequate time for any
software download that may be necessary.  
About Sarepta Therapeutics  
Sarepta Therapeutics is focused on developing first-in-class
RNA-based therapeutics to improve and save the lives of people
affected by serious and life-threatening rare and infectious
diseases. The Company's diverse pipeline includes its lead program
eteplirsen, for Duchenne muscular dystrophy, as well as potential
treatments for some of the world's most lethal infectious diseases.
Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs.
For more information, please visit us at www.sareptatherapeutics.com. 
Sarepta Investor Contact:
Erin Cox
425.354.5140
ecox@sareptatherapeutics.com 
Sarepta Media Contact:
Jim Baker
617.444.8424 ext 3124
jbaker@sareptatherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.